Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 10 versus INAPSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 10 versus INAPSINE.
ETRAFON 2-10 vs INAPSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON 2-10 is a combination of the phenothiazine antipsychotic perphenazine and the tricyclic antidepressant amitriptyline. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic neurotransmission in the mesolimbic pathway, while amitriptyline inhibits serotonin and norepinephrine reuptake, enhancing monoaminergic signaling.
Butyrophenone antipsychotic; antagonizes dopamine D2 receptors in the CNS, also exhibits alpha-adrenergic blocking activity.
1-2 tablets (perphenazine 2 mg / amitriptyline 10 mg) orally 3-4 times daily; max 8 tablets/day.
IM: 2.5-10 mg every 3-4 hours as needed; IV: 2.5-10 mg slow IV push (over 2-3 minutes), repeat every 30-60 minutes as needed; maximum total dose 20 mg.
None Documented
None Documented
The terminal elimination half-life is approximately 9-10 hours for perphenazine and 18-24 hours for amitriptyline; amitriptyline's active metabolite nortriptyline has a half-life of 18-44 hours, necessitating once-daily dosing for maintenance.
Terminal elimination half-life is 10-22 hours (mean 14.5 hours) in adults; may be prolonged in elderly or patients with hepatic impairment.
Elimination is primarily renal (50-70% as metabolites, <5% unchanged) and biliary/fecal (30-50% as metabolites).
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal excretion accounts for approximately 20-30%.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic